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Abstract
Background: CMT-2 is a clinically and genetically heterogeneous group of peripheral axonal neuropathies
characterized by slowly progressive weakness and atrophy of distal limb muscles resulting from length-dependent
motor and sensory neurodegeneration. Classical giant axonal neuropathy (GAN) is an autosomal recessively
inherited progressive neurodegenerative disorder of the peripheral and central nervous systems, typically diagnosed
in early childhood and resulting in death by the end of the third decade. Distinctive phenotypic features are the
presence of “kinky” hair and long eyelashes. The genetic basis of the disease has been well established, with over
40 associated mutations identified in the gene GAN, encoding the BTB-KELCH protein gigaxonin, involved in
intermediate filament regulation.
Methods: An Illumina Human CytoSNP-12 array followed by whole exome sequence analysis was used to identify
the disease associated gene mutation in a large consanguineous family diagnosed with Charcot-Marie-Tooth
disease type 2 (CMT-2) from which all but one affected member had straight hair.
Results: Here we report the identification of a novel GAN missense mutation underlying the CMT-2 phenotype
observed in this family. Although milder forms of GAN, with and without the presence of kinky hair have been
reported previously, a phenotype distinct from that was investigated in this study. All family members lacked common
features of GAN, including ataxia, nystagmus, intellectual disability, seizures, and central nervous system involvement.
Conclusions: Our findings broaden the spectrum of phenotypes associated with GAN mutations and emphasize a
need to proceed with caution when providing families with diagnostic or prognostic information based on either
clinical or genetic findings alone.
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Background
The classical form of giant axonal neuropathy [GAN,
MIM #256850], is an autosomal recessive progressive
neurodegenerative condition of the peripheral and cen-
tral nervous systems [1]. A distinctive feature of the
phenotype is the presence of “kinky” hair (tightly curled
lacklustre hair distinctive from that of the parents) and
long eyelashes. Central nervous system (CNS) involve-
ment is variable and includes optic atrophy, nystagmus,
intellectual disability and spasticity [1]. GAN is an
axonal neuropathy that is typically of infantile onset and
diagnosed in early childhood [2, 3] with most affected
children becoming wheelchair dependent by the second
decade [3, 4]. The classical form results in death in the
third decade. Sural nerve biopsies taken from GAN pa-
tients, exhibit reduced density of nerve fibres and the
presence of disproportionally large axons resulting from
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accumulation of neurofilaments [5, 6]. The causative gene
was identified in 2000 [7] and over 40 different GAN mu-
tations have been discovered in GAN patients with some
variability in phenotype [8, 9]. Charcot-Marie-Tooth dis-
ease (CMT; also known as hereditary motor and sensory
neuropathy) is a clinically and genetically heterogeneous
group of peripheral neuropathies characterized by a
length-dependent degeneration of motor and sensory neu-
rons, which results in slowly progressive distal sensory
loss, and weakness and atrophy of the distal limb muscles.
With an estimated global prevalence of 1 in 2500, CMT is
the most commonly inherited disorder of the peripheral
nervous system and may show autosomal dominant, re-
cessive and X-linked modes of inheritance. Clinically,
CMT has been divided into two main subtypes; the de-
myelinating neuropathies (CMT-1, CMT-3, CMT-4 and
CMT-X) characterized by severely reduced motor nerve
conduction velocities (mNCVs) (<38 m/s), and axonal
neuropathies (CMT-2) in which mNCVs are normal or
only slightly reduced in association with reduced ampli-
tude of compound motor action potentials (CMAPs). In
demyelinating disease, the most frequently implicated
genes in this subgroup are PMP22, MPZ and GJB1. In the
axonal form 20% of cases are caused by mutations in
MFN2, a dominant form, and all other forms are rare
resulting from mutations in over 18 genes identified to
date. It is also recognized that some genes can cause both
an axonal and a demyelinating phenotype e.g. GDAP1.
With the application of more widespread genetic testing,
broadening of the phenotypic spectrum that can be seen
in association with mutations in GAN is coming to light
[10]. Recently Roth and colleagues identified two patients
with biallelic mutations in GAN, amongst a cohort of 13
who all had straight hair [11]. These individuals had nor-
mal intellect which lead the authors to propose that the
absence of “kinky” hair correlated with a lower prevalence
of significant CNS involvement.
Here, we report the identification of a novel missense
mutation c.103G > T; p.Val35Phe in GAN (NC_000016.
10:g.81315216G>T; NM_022041.3:c.103G>T; p.Val35Phe),
as the underlying cause of sensory-motor axonal neur-
opathy in a large consanguineous family apparently
affected by CMT-2. Whilst affected family members all
present with classical features of neuropathy including
distal weakness and foot deformity, it is noted that deep
tendon reflexes (DTRs) were preserved and neither nys-
tagmus, ataxia, nor changes in white matter on magnetic
resonance imaging (MRI) studies were seen. Further all
but one affected member of the family had straight hair.
Methods
Patients and family members
This report describes genetic and clinical investigations
in an extended consanguineous Muslim Arab family
from a single clan residing in a small village in Israel
(Fig. 1). Detailed neurological, electrophysiological, and
imaging studies were performed on the patients as well
as on unaffected family members.
Molecular genetic analysis
In order to map the chromosomal location of the patho-
genic variant, samples from the family were genotyped
using an Illumina Human CytoSNP-12 array incorporat-
ing ~330,000 genetic markers, according to the manu-
facturer’s protocol.
In order to identify the disease associated gene, whole-
exome sequencing was performed on a single affected
individual in this family (subject III:12, Fig. 1) to generate
a profile of variants not present in publically available
databases and rare sequence variants. Coding regions
were captured by HiSeq2000 using paired-end (2 x 100)
protocol at a mean coverage depth of 30X at Otogenetics
Corporation (Norcross, GA, USA). The Agilent SureSelect
Human All ExonV4 (51 Mb) enrichment kit was used for
Fig. 1 Family pedigree and c.103G > T co-segregation. Extended family pedigree of the Israeli family investigated with genotypes showing the
presence or absence of GAN c.103G > T in affected and unaffected subjects respectively, who have been included in this study
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exome enrichment. Sequence reads were aligned to the
human genome reference sequence [hg19] and read
alignment, variant calling, and annotation were per-
formed by DNAnexus (DNAnexus Inc., Mountain
View, CA; https://dnanexus.com)
Results
Clinical and electrophysiological findings
All clinical findings are presented in Table 1; electro-
physiological findings are presented in Table 2.
Index patients: IV:14 and IV:15
The index patients (IV:14, IV:15) are dizygotic twins, born
to consanguineous parents (first cousins) after an unevent-
ful pregnancy and delivery. Gross motor development was
slow (both walked at age 30 months), but fine motor and
speech development was normal. Both attended regular
school, and academic performance was satisfactory.
The patients initially presented at our clinic at age
6 years for evaluation of abnormal gait. On physical
examination, no dysmorphic features were noted. Hair
was normal and not kinky. There were no cranial nerve
abnormalities and no signs of nystagmus. Weakness of
the ankle and toe extensors and flexors, peroneus mus-
cles, and tibialis posterior muscles was documented
(Medical Research Council grade 4/5), with slightly de-
creased vibration. DTRs were elicited. Pes planus was
noted. Both patients exhibited a crouched gait pattern
with externally rotated feet. Cerebellar function was nor-
mal. Neurophysiological studies revealed normal motor
and sensory nerve conduction velocities, in association
with a reduced amplitude CMAP of the right tibial nerve
in patient IV:14 and of the right peroneal nerve in
patient IV:15. MRI of the brain did not reveal white
matter changes.
Tendon-lengthening surgery was performed to treat
the contractures. The most recent follow-up evaluation
was conducted at age 15 years. The distal weakness was
more pronounced, although the patients were still
ambulatory. One of the twins was overweight, further
exacerbating his walking difficulties.
Patient III:12 – Father of the index patients
The father of the index patients (patient III:12), whose
parents were also consanguineous, had been diagnosed
with Charcot-Marie-Tooth and was wheelchair-bound
by age 12 years. He completed 12 years of school despite
mild learning difficulties.
Examination at the time of admission of the index pa-
tients, at age 33 years, revealed no dysmorphic features
or hair abnormalities. Findings on cranial nerve examin-
ation were normal. Atrophy of the upper limbs was doc-
umented, with weakness of the small hand muscles,
mainly interosseous. Vibration was slightly reduced, but
Table 1 Summary of clinical data in affected and unaffected subjects
Individual c.103 Sex (M/F) Onset Distal
weakness
DTR Kinky hair Foot
deformity
Nystagmus MRI white
matter changes
Ataxia Other features
Affected Individuals
III:2* T/T M 1st decade +++ - UE - Yes No N/A No Facial weakness.
Speech difficulties
+ pat
- acill
III:12 T/T M 1st decade +++ + - Yes No N/A No
IV:14 T/T M 6y ++ + - Yes No No No
IV:15 T/T M 6y ++ + - Yes No No No
IV:18 T/T M 4y + ++ curly Yes No No No
Unaffected Individuals
III:1 G/G F - - ++ - No No N/A No
III:9 G/G M - - ++ - No No N/A No
III:11 G/T M - ++ - No No N/A No
III:13 G/T F - - ++ - No No N/A No
IV:1 G/T F - - ++ - No No N/A No
IV:2 G/T F - - ++ - No No N/A No
IV:3 G/T F - - ++ - No No N/A No
IV:16 G/T F - - ++ - No No N/A No
IV:17 G/T M - - ++ - No No N/A No
*Individual III:2 is the father of individuals IV:14, IV:15, and IV:18 (see Fig. 1)
DTR deep tendon reflexes, UE upper extremities, pat patella, acill Achilles, N/A not available
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sensation was otherwise normal. The lower limbs exhib-
ited normal proximal muscle strength but severe weakness
of the ankle and toe flexors and extensors, in addition to
reduced vibration and proprioception of the toes. Deep
tendon reflexes were elicited. Neurophysiology studies
demonstrated widespread severe, predominantly axonal,
sensorimotor neuropathy more marked in the legs.
Patient IV:18 – Brother of the index patients
The brother of the index patients (IV:18) presented to
our clinic at age 4 years because of maternal concerns
about gross motor impairment, similar to findings in his
older brothers. He fell frequently. Past medical history
revealed an uneventful pregnancy and delivery. Walking
started at age 18 months and speech was delayed. He
had moderately curly hair but it was not neither kinky nor
frizzy. Other than curly hair, there were no dysmorphic
features. Distal weakness was noted in the lower limbs
with preserved reflexes, in addition to pes planus,
crouched gait, and externally rotated feet. Babinski sign
was positive. Neurophysiology studies performed at age
8 years demonstrated a mild axonal motor sensory poly-
neuropathy in the legs and arms with a mild-moderate
reduction in compound motor action potential amplitude
and absence of sensory conduction. Needle electromyog-
raphy revealed no abnormalities except for mild early
chronic reinnervation in the right tibialis anterior muscle.
MRI of the brain was normal, with no apparent white
matter changes.
Patient III:2 – Paternal uncle of the index patients
The index patients’ paternal uncle. He had frequent falls
in childhood and later complained of hand weakness. He
was wheelchair-bound in his mid-twenties. Although he
was not diagnosed with learning difficulties, he did not
proceed to high school. Examination at age 39 years, a
few years after our index patients' admission, revealed
no dysmorphic features or hair abnormalities. Mild facial
weakness and speech dysarthria was noted. Atrophy of
the upper limbs was documented with weakness of the
small hand muscles, mainly interosseous. The lower
limbs exhibited mild proximal muscle weakness, severe
distal weakness, in addition to reduced sensation vibra-
tion and proprioception of the toes. DTRs were not elic-
ited in the upper limbs. Neither were they elicited in the
left patella and both Achilles tendons, however this is
Table 2 Electrophysiological data
Individual Age (years) Latency (ms) CMAP (mV) Motor nerve velocity (m/s) Sensory nerve latency (ms) SNAP (μV)
II:9 70 Median-4.6 (n < 4.2) Median-13.9 (n > 4) Median- 52 (n >49) Median- 3.8 (n < 2.5) Median-2.4
Ulnar- 3.7 (n) Ulnar-8.3 (n > 6) Ulnar-52 (n) Ulnar-3.5 (n < 2.1)
Peroneal- 5.9 (n < 5.2) Peroneal-1.7 (n > 2) Peroneal-33 (n > 40) Sural-absent Sural- absent
II:10 70 Median 10.8 Median-1.5 Median- 38 Median – N/A Median-absent
Ulnar-3.6 (n) Ulnar-10 Ulnar-.56 (n) Ulnar-2 Ulnar-6.2
Peroneal-5.1 Peroneal- 1 Tibial- 42 Sural-2.9 (n < 3.2) Sural-19
III:12* 33 Median-5.5 Median-5.4 Median- 55.6 absent absent
Ulnar- 5.6 Ulnar-1.5 Ulnar-50
Tibial& peroneal- N/A Tibial-absent Tibial-absent
Peroneal- absent Peroneal- absent
IV:14* 6 Median-3.1 Median-6.1 Median- 60.7 Median- 2.8 Median-22
Ulnar-2.8 Ulnar-5 Ulnar-60 Ulnar-2.4 Ulnar-25
Tibial-4.2 Tibial-1.3 Tibial-35.6
Peroneal-4.1 Peroneal-56.4
normal
IV:15* 6 Median-3.7 Median-5.7 Median- 51.7 Median- 3 Median-56
Ulnar- 2.9 Ulnar-6.3 Ulnar- 66 Ulnar-3 Ulnar-42
Tibialis-5.1 Tibialis-3.1 Tibial- 41.8 Sural-3.5 Sural-9.9
Peroneal-4.1 Peroneal-0.5 Peroneal- 47.7
IV:18* 8 Median-4.5 Median-3.6 Median-64 absent absent
Tibialis-4.4 Tibialis-1.4 Tibialis-50
Peroneal-5.7 Peroneal-2.1 Peroneal-59
*Affected individual
N/A not available
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attributed to tendon-lengthening surgery. Foot deformity
was noted.
Genetic findings
Inspection of the SNP genotypes of affected family
members identified a single notable homozygous region
of 2.15 Mb on chromosome 16q23.2-23.3, delimited by
markers rs889518 and rs4783311 (Chr16:80,897,297-
83,051,118 [hg38]), shared solely by affected individuals
in the family. Multipoint linkage analysis was performed
with Simwalk2 [12], using the SNP genotype data, as-
suming autosomal recessive inheritance, full penetrance
and a disease allele frequency of 0.00001, achieving a
LODMAX = 2.71 corresponding to the autozygous region.
This region contains 31 genes and was considered very
likely to harbor the pathogenic variant. After filtering,
exome sequencing of DNA from a single affected indi-
vidual identified only one likely deleterious variant
within the 16q23.2-23.3 region, a single base substitution
(NC_000016.10:g.81315216G > T; NM_022041.3:c.103G >
T; p.Val35Phe) in GAN. Dideoxy sequence analysis con-
firmed co-segregation of the variant with the disease
phenotype in the family with unaffected family members
being wildtype or heterozygous for the variant. The vari-
ant is not present in genomic databases (Exome Variant
Server, EVS; dbSNP; Human Gene Mutation Database,
HGMD; ExAC). The c.103G > T nucleotide alteration is
predicted to affect a stringently conserved amino acid
across all species examined, and substitute a valine at
codon 35 to phenylalanine (p.Val35Phe, Fig. 2). In silico
mutation analysis provided conflicting predictions as to
the functional outcome of the variant on the gigaxonin
protein: PolyPhen-2 [13] HumDiv and HumVar both
predicted the variant to be benign with scores of 0.108
and 0.021 respectively, while SIFT and PROVEAN [14]
predicted the variant to be disease causing with scores of
0.017 and −2.78, respectively.
Unaffected family members had either a homozygous
normal (G/G) phenotype or heterozygous G/T genotype,
consistent with the recessive mode of inheritance of
GAN. None presented any distal weakness, foot deform-
ity, ataxia or nystagmus.
Discussion
In this work, a novel sequence alteration in the gene
GAN, c.103G > T, was identified as most likely the
underlying cause for a sensory-motor axonal neuropathy
in a large consanguineous family presenting as CMT-2.
Affected family members were all male, homozygous for
the mutation and all presented with distal weakness,
more pronounced in older individuals (generation III),
consistent with the progressive nature of GAN. They all
had foot deformities but none had nystagmus or ataxia
and all had preserved DTR. Findings in clinical and im-
aging analyses, as well as medical history did not suggest
CNS involvement. There was no evidence of significant in-
tellectual disability or seizures. MRI studies, available only
for the two index patients and their brother revealed no
white matter changes. Nerve conduction studies showed
reduced amplitudes with prolonged distal latencies and
normal or prolonged conduction velocities which is con-
sistent with axonal motor-sensory neuropathy.
The clinical presentation of affected individuals in this
current family differs from the consanguineous Arab-
Israeli family with GAN described by Abu Rashid and
colleagues [8]. Although an intermediate phenotype,
their patients had kinky hair, thick eyelashes and thick
eyebrows, ataxia, spasticity and MRI changes, all charac-
teristic of GAN and CNS involvement.
The gene GAN encodes the protein gigaxonin, a BTB-
KELCH protein that plays a role in regulating intermedi-
ate filaments (IFs) [15] and the degradation of MAP1B
light chain, which is critical to neuronal survival [16].
Based on sequence homology, it is predicted to be a sub-
strate adaptor for Cul3-E3 ubiquitin ligase, and hypothe-
sized to be involved in the ubiquitination and degradation
of several IF proteins, including vimentin [17].
The c.103G > T nucleotide change is predicted to
affect a stringently conserved amino acid across all spe-
cies examined, and substitute a valine at residue 35 to
phenylalanine (p.Val35Phe) within the BTB-domain of
the protein. The BTB-domain has been established as
the proteins homodimerization domain [18, 19], as well
as its site of interaction with the E3 ligase, MYCBP2,
and the heat shock proteins, HSP90AA1 and HSP90AB1
Fig. 2 Protein homology of GAN in various species and the p.Val35Phe mutant molecule. The mutation results in an amino acid substitution at
Valine (indicated by the red box) to phenylalanine at position 35, a residue highly conserved across species
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[20]. Boizot and colleagues showed that missense muta-
tions in this region (p.Arg15Ser and p.Ala49Glu) can lead
to destabilization of the protein resulting in a shorter half-
life and lowered protein abundance [19]. Their predictions
support the in-silico prediction of SIFT and PROVEAN
[14] that our p.Val35Phe variant is disease-causing. Of
note, they describe the phenotype of the p.Arg15Ser muta-
tion as a moderate form of GAN, somewhat similar to
ours, with very slow progression, no central nervous
impairment and extended survival. Roth and colleagues
[11] conducted a GAN natural history study on 13
patients, two of whom (c.130C > T, p.Gln44X; c.1420G >
C, p.Gly474Arg; c.971C > T, p.Ala324Val; c.1391G >A,
p.Cys464Tyr) lacked the characteristic tightly curly (kinky)
hair. These patients’ gross motor function measure was
better than those with curly hair in the cohort and defined
their phenotype as milder. Both straight-haired patients in
the Roth study had a distinctly different phenotype from
ours (including occolomotor apraxia as compared to
complete absence of ocular signs in our patients).
Zemmouri and colleagues [21] have described a
consanguineous Algerian family with a CMT2-like
presentation of GAN, characterized by late onset and little
to no involvement of CNS. They were able to establish a
linkage to the chromosome 16q locus, however, they did
not find the exact nature of the mutation which was
reported by Bormont and colleagues the same year [7].
In this study we found a novel missense mutation in
the gene GAN in a consanguineous family that is most
likely the underlying cause of a CMT2-like presentation
of GAN. In the post- genomics era with easy access to
gene panels and exome sequencing for clinical investiga-
tion the family presented here serves to highlight the need
to proceed with caution when giving out prognostic infor-
mation based on the genetic findings. The spectrum of
phenotypes associated with mutations in many genes is
broadening due to our ability to identify these variants
with whole exome/genome sequencing in the absence of
the classical phenotype. Classical GAN is a devastating
disease but the family described here and reports of fam-
ilies such as documented by Roth and Abu-Rashid
emphasize the need to acknowledge a wider phenotypic
spectrum when counseling such families.
Further research is needed to elucidate the molecular
mechanisms mediating the effects of mutations in spe-
cific Gigaxonin protein domains on aspects of the GAN
disease presentation.
Conclusion
Our findings broaden the spectrum of phenotypes asso-
ciated with GAN mutations and emphasize a need to
proceed with caution when providing families with diag-
nostic or prognostic information based on either clinical
or genetic findings alone.
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